# NM_006768.5(BRAP):c.1353G>A (p.Lys451=)

https://sugi.bio/variant/brap-p-lys451

## Summary

**BRAP p.Lys451= (c.1353G>A)** is classified **Benign** in BRAP (ClinVar, Multiple submitters, 3 submitters; last evaluated 2018-05-08). Common (popmax 5.3%, afr) — too common for a highly-penetrant pathogenic allele.

**At a glance:** Benign · review: Multiple submitters · rsID rs61739319 · 3 submitters · common (popmax 5.3%, afr) — too common for a highly-penetrant pathogenic allele

## For patients & families {#patients}

This is a change in the BRAP gene that is classified as benign — not considered disease-causing, submitted by 3 submitters.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

**Support & next steps:** [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [BRAP](https://sugi.bio/atlas/gene/BRAP/) |
| Protein change (HGVS p.) | p.Lys451= |
| Coding change (HGVS c.) | c.1353G>A |
| MANE Select transcript | [NM_006768](https://www.ncbi.nlm.nih.gov/nuccore/NM_006768) |
| dbSNP | [rs61739319](https://www.ncbi.nlm.nih.gov/snp/rs61739319/) |
| Variant type | single nucleotide variant |
| Location | chr12:111650001-111650001 (GRCh38) |
| ClinVar | [VCV768584](https://www.ncbi.nlm.nih.gov/clinvar/variation/768584/) |

**All HGVS expressions:** `NC_000012.11:g.112087805C>T`, `NC_000012.12:g.111650001C>T`, `NM_006768.5:c.1353G>A`

## Computational & population evidence {#evidence}

**Concordance:** Evidence sources **disagree** — common (popmax 5.3%, afr) — too common for a highly-penetrant pathogenic allele.

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation (below), not from a missing predictor score.
- Conservation: phyloP -0.083, GERP -3.35, phastCons 0.799 — not a conserved position (phyloP < 0.1, ACGS BP7 cut)
- CADD: **PHRED 4.732**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI: **no splice effect predicted**. SpliceAI outputs four numbers per variant, not one: acceptor loss, donor loss, acceptor gain, donor gain (DS_AL / DS_DL / DS_AG / DS_DG). A loss score is an existing splice site weakened or destroyed; a gain score is a new site created or an existing one strengthened. The release publishes its own filter rule, which we read from the dataset rather than assume: an allele is reported only if the largest of its four deltas reaches 0.2. No allele at this position is in the release, so all four are under 0.2 for every alternate allele here. No figure is shown because none was read: the bound is deduced from that absence. It is a result, not a gap in our data, because the release scores every possible substitution across the transcripts it covers (Ensembl MANE v1.4) before it filters, so what survives for a gene is one continuous stretch. What is measured is that this position sits inside the stretch covered for BRAP (559 scored positions, the nearest 42 bases away); what is taken from the release's own description, rather than measured, is that coverage inside that stretch is continuous. On that, SpliceAI did score it. *ClinGen's SVI treats the largest of the four as evidence against a splicing effect at or below 0.1, where it may support BP4, and as uninformative between 0.1 and 0.2. We cannot tell which applies here, so these SpliceAI data support neither BP4 nor PP3; that is a statement about this evidence alone, not about the variant's other evidence.*
- Population frequency (gnomAD v4.1): grpmax **5.3%** (afr) · FAF95 5.16% · FAF99 5.11% · 3,974/74,956 in the highest group · 4,649/1,611,846 alleles overall — common (popmax 5.3%, afr) — too common for a highly-penetrant pathogenic allele.

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| African / African-American (grpmax) | 5.3% | 19 |
| Remaining individuals (not grpmax-eligible) | 0.437% | 229 |
| Middle Eastern | 0.413% | 242 |
| Admixed American | 0.379% | 264 |
| South Asian | 0.0132% | 7,569 |
| European (non-Finnish) | 0.0117% | 8,540 |

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**BRAP** population constraint: LOEUF 0.766, pLI 4.0417e-06, missense-Z 2.0636. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

## Protein context {#protein}


AlphaFold model confidence (whole protein): pLDDT 76.92, 33% of residues very-high.

## What this gene does {#gene-function}

*Describes the biological roles of BRAP (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** BRAP's established molecular role includes ubiquitin-protein transferase activity. In Reactome, BRAP is annotated in disease pathway(s) including **Paradoxical activation of RAF signaling by kinase inactive BRAF**, **Signaling by moderate kinase activity BRAF mutants**.

**Disease mechanism (Reactome):** BRAP loss or alteration is curated in [Paradoxical activation of RAF signaling by kinase inactive BRAF](https://reactome.org/content/detail/R-HSA-6802955), [Signaling by moderate kinase activity BRAF mutants](https://reactome.org/content/detail/R-HSA-6802946), [Signaling downstream of RAS mutants](https://reactome.org/content/detail/R-HSA-9649948).

### Pathways affected {#pathways}

BRAP participates in **5 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| ⚕ [Paradoxical activation of RAF signaling by kinase inactive BRAF](https://reactome.org/content/detail/R-HSA-6802955) | curated |
| ⚕ [Signaling by moderate kinase activity BRAF mutants](https://reactome.org/content/detail/R-HSA-6802946) | curated |
| ⚕ [Signaling downstream of RAS mutants](https://reactome.org/content/detail/R-HSA-9649948) | curated |
| [Negative regulation of MAPK pathway](https://reactome.org/content/detail/R-HSA-5675221) | curated |
| [RAF activation](https://reactome.org/content/detail/R-HSA-5673000) | curated |

### Molecular function & processes (GO — experimentally supported) {#go}

**Molecular function:** ubiquitin-protein transferase activity, obsolete nuclear localization sequence binding, identical protein binding, ubiquitin protein ligase activity.

**Biological process:** MAPK cascade, Ras protein signal transduction, negative regulation of signal transduction, protein ubiquitination.

## Clinical significance {#significance}

**Benign** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2018-05-08.

**Submitter consensus:** unanimous (2/2 Benign).

**Submission history:** 11 submissions (2018); classifications have differed over time.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Dr. Peter K. Rogan Lab, Western University |  | no classification provided | in vitro |  |
| Labcorp Genetics (formerly Invitae), Labcorp | Benign | criteria provided, single submitter | clinical testing | 2018-05-08 |
| Breakthrough Genomics, Breakthrough Genomics | Benign | criteria provided, single submitter | not provided |  |

**Reported phenotype names (ClinVar):** not provided, Clear cell carcinoma of kidney, Gastric cancer, Ovarian serous cystadenocarcinoma, Malignant tumor of esophagus, Uterine corpus endometrial carcinoma, Cervical cancer, none provided.

## Similar variants {#similar}

Related BRAP variant pages (same residue, condition, or type): [BRAP p.Ala42=](/variant/brap-p-ala42), [BRAP p.Gly250=](/variant/brap-p-gly250), [BRAP p.Ile193=](/variant/brap-p-ile193), [BRAP p.Ala100Val](/variant/brap-p-ala100val), [BRAP p.Ala379Val](/variant/brap-p-ala379val), [BRAP p.Ala403Ser](/variant/brap-p-ala403ser), [BRAP p.Ala481Gly](/variant/brap-p-ala481gly), [BRAP p.Ala565Thr](/variant/brap-p-ala565thr).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-15); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 768584). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*